These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 33883257)
41. Amino acid-dependent NPRL2 interaction with Raptor determines mTOR Complex 1 activation. Kwak SS; Kang KH; Kim S; Lee S; Lee JH; Kim JW; Byun B; Meadows GG; Joe CO Cell Signal; 2016 Feb; 28(2):32-41. PubMed ID: 26582740 [TBL] [Abstract][Full Text] [Related]
42. Nudix-type motif 2 contributes to cancer proliferation through the regulation of Rag GTPase-mediated mammalian target of rapamycin complex 1 localization. Kwon O; Kwak D; Ha SH; Jeon H; Park M; Chang Y; Suh PG; Ryu SH Cell Signal; 2017 Apr; 32():24-35. PubMed ID: 28089905 [TBL] [Abstract][Full Text] [Related]
43. PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Geng G; Xu C; Peng N; Li Y; Liu J; Wu J; Liang J; Zhu Y; Shi L Immunology; 2021 May; 163(1):74-85. PubMed ID: 33421118 [TBL] [Abstract][Full Text] [Related]
44. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733 [TBL] [Abstract][Full Text] [Related]
45. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741 [TBL] [Abstract][Full Text] [Related]
47. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Zhang YX; Zhao YY; Shen J; Sun X; Liu Y; Liu H; Wang Y; Wang J Nano Lett; 2019 May; 19(5):2774-2783. PubMed ID: 30943039 [TBL] [Abstract][Full Text] [Related]
48. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351 [TBL] [Abstract][Full Text] [Related]
49. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Zhou J; Kryczek I; Li S; Li X; Aguilar A; Wei S; Grove S; Vatan L; Yu J; Yan Y; Liao P; Lin H; Li J; Li G; Du W; Wang W; Lang X; Wang W; Wang S; Zou W Nat Immunol; 2021 Apr; 22(4):460-470. PubMed ID: 33767425 [TBL] [Abstract][Full Text] [Related]
50. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Jewell JL; Kim YC; Russell RC; Yu FX; Park HW; Plouffe SW; Tagliabracci VS; Guan KL Science; 2015 Jan; 347(6218):194-8. PubMed ID: 25567907 [TBL] [Abstract][Full Text] [Related]
51. Multifaceted Role of BTLA in the Control of CD8 Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817 [No Abstract] [Full Text] [Related]
52. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity. Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M Front Immunol; 2021; 12():695056. PubMed ID: 34276686 [TBL] [Abstract][Full Text] [Related]
53. HDAC9 deficiency promotes tumor progression by decreasing the CD8 Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611 [TBL] [Abstract][Full Text] [Related]
54. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559 [TBL] [Abstract][Full Text] [Related]
55. SAR1B senses leucine levels to regulate mTORC1 signalling. Chen J; Ou Y; Luo R; Wang J; Wang D; Guan J; Li Y; Xia P; Chen PR; Liu Y Nature; 2021 Aug; 596(7871):281-284. PubMed ID: 34290409 [TBL] [Abstract][Full Text] [Related]
56. DAPK1 (death associated protein kinase 1) mediates mTORC1 activation and antiviral activities in CD8 Wei Z; Li P; He R; Liu H; Liu N; Xia Y; Bi G; Du Q; Xia M; Pei L; Wang J; Wang G; Tang ZH; Cheng X; Li H; Li Z; Ye L; Laurence A; Lu Y; Yang XP Cell Mol Immunol; 2021 Jan; 18(1):138-149. PubMed ID: 31541182 [TBL] [Abstract][Full Text] [Related]
57. Endogenous Glucocorticoid Signaling Regulates CD8 Acharya N; Madi A; Zhang H; Klapholz M; Escobar G; Dulberg S; Christian E; Ferreira M; Dixon KO; Fell G; Tooley K; Mangani D; Xia J; Singer M; Bosenberg M; Neuberg D; Rozenblatt-Rosen O; Regev A; Kuchroo VK; Anderson AC Immunity; 2020 Sep; 53(3):658-671.e6. PubMed ID: 32937153 [TBL] [Abstract][Full Text] [Related]
58. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474 [TBL] [Abstract][Full Text] [Related]
59. IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8 Liang Y; Wang X; Wang H; Yang W; Yi P; Soong L; Cong Y; Cai J; Fan X; Sun J Immunology; 2022 Jan; 165(1):61-73. PubMed ID: 34411293 [TBL] [Abstract][Full Text] [Related]
60. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]